Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
4.200
-0.110 (-2.55%)
Aug 28, 2026, 1:22 PM EDT - Market open
Psyence Biomedical Employees
Psyence Biomedical had 12 employees as of March 31, 2025.
Employees
12
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$578,035
Market Cap
16.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Citius Pharmaceuticals | 23 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| CalciMedica | 16 |
| BioVie | 13 |
| Lexaria Bioscience | 7 |
| Akari Therapeutics, | 6 |
PBM News
- 2 days ago - Psyence Biomedical files to sell 1.15M common shares for holders - TheFly
- 9 days ago - Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development - GlobeNewsWire
- 2 months ago - Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform - Business Wire
- 3 months ago - Psyence Biomedical announces U.S. engagement initiative focused on ibogaine - TheFly
- 3 months ago - Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing - GlobeNewsWire
- 4 months ago - Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder - GlobeNewsWire
- 4 months ago - Psyence Biomedical provides update on position in global ibogaine market - TheFly
- 4 months ago - Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source - GlobeNewsWire